Pentagon Extends Anthrax Vaccine Supply Deal

The contract modification keeps BioThrax doses flowing to military customers, with deliveries set for 2026 and 2027.

Updated on Nov. 4, 2026 in COVID-19

Isometric editorial illustration of a single glass vaccine vial beside a stack of plain gray supply crates on a cream background, suggesting a military vaccine stockpile.
The Pentagon extended its contract with Emergent BioSolutions worth up to $22.3 million to keep supplying BioThrax anthrax vaccine to the U.S. Defense Department through 2027. AI Illustration. Upload story photo >

Emergent BioSolutions received a contract modification worth up to $22.3 million to supply its BioThrax anthrax vaccine to the U.S. Defense Department. The modification exercises an option period under an existing Pentagon contract and includes an initial delivery valued at about $7.4 million set for 2026.

Why it matters

The contract keeps a licensed anthrax vaccine in supply for military use, a preventive measure against a rare but serious bacterial threat. Because the modification extends an existing agreement rather than starting a new one, it reflects continued government investment in stockpiling protective vaccines.

The figures come from a Pentagon contract modification that exercises an option under an existing agreement. The source does not report clinical study data, as this is a procurement action rather than a research finding.

The players

Emergent BioSolutions

Emergent BioSolutions is a biopharmaceutical company that develops and manufactures vaccines and countermeasures against infectious diseases and biological threats, including the BioThrax anthrax vaccine.

U.S. Department of Defense

The Department of Defense is the federal agency responsible for military readiness, including procurement of medical countermeasures such as vaccines to protect service members from biological threats.

The details

BioThrax is an anthrax vaccine, and the modification exercises an option period under an existing contract with the Defense Department. The contract structure lets the government order additional doses over time within a pre-negotiated framework, with deliveries staged across 2026 and 2027.

Timeline

  1. 2026: Initial delivery of BioThrax valued at about $7.4 million

  2. 2027: Remaining BioThrax deliveries expected

Health Landscape

Anthrax vaccines like BioThrax are maintained largely for defense and high-risk occupational groups rather than routine public immunization. Government procurement contracts such as this one are a standard way the United States keeps medical countermeasures for biological threats in stock.

Anthrax vaccination is generally relevant to military personnel and certain high-risk workers rather than the general public. Anyone with questions about whether anthrax vaccination applies to their occupation or travel should raise it with their physician or occupational health provider.

The takeaway

Government stockpiling of protective vaccines is a routine preparedness measure against rare biological threats. If you are in an occupation with possible anthrax exposure, ask your clinician or employer whether vaccination is recommended for you.

Further reading

For broader context on government vaccine stockpiling and preparedness, see the COVID-19 section.

Source note: This article includes information reported by Morningstar.